News
BIIB
176.02
-2.50%
-4.52
UPDATE 1-US FDA's accelerated approval for drugs needs more transparency, says research firm
Reuters · 16h ago
3 Stocks With Upgraded Broker Ratings As Markets Hit All-Time High
NASDAQ · 20h ago
US FDA's accelerated approval for drugs needs more transparency, says research firm
Reuters · 20h ago
Analysts Offer Insights on Healthcare Companies: Medtronic (MDT), Immunovant (IMVT) and Biogen (BIIB)
TipRanks · 20h ago
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Biogen (BIIB) and Nkarta (NKTX)
TipRanks · 21h ago
This Healthcare Stock Has Made Long-Term Investors Rich -- Can It Keep Doing It?
The Motley Fool · 22h ago
How Biogen’s Alloy ASO Deal Could Shape Its Neurology Pipeline Will Impact Biogen (BIIB) Investors
Simply Wall St · 22h ago
Biogen raised to Overweight at Piper Sandler on Apellis buyout
Seeking Alpha · 2d ago
Tesla upgraded, AppLovin initiated: Wall Street’s top analyst calls
TipRanks · 2d ago
This Tesla Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Tuesday
Benzinga · 2d ago
Biogen Price Target Raised to $214.00/Share From $177.00 by Piper Sandler
Dow Jones · 2d ago
Biogen Raised to Overweight From Neutral by Piper Sandler
Dow Jones · 2d ago
Piper Sandler Upgrades Biogen to Overweight, Raises Price Target to $214
Benzinga · 2d ago
U.S. RESEARCH ROUNDUP-Biogen, Equinix, Revolution Medicines
Reuters · 3d ago
BIOGEN <BIIB.O>: PIPER SANDLER RAISES TO OVERWEIGHT FROM NEUTRAL; RAISES TARGET PRICE TO $214 FROM $177
Reuters · 3d ago
Biogen upgraded to Overweight from Neutral at Piper Sandler
TipRanks · 3d ago
BUZZ-U.S. STOCKS ON THE MOVE-Conagra, Oracle, Replimune
Reuters · 3d ago
Biogen Is Maintained at Neutral by Citigroup
Dow Jones · 3d ago
Biogen Is Maintained at Hold by Truist Securities
Dow Jones · 3d ago
Biogen Price Target Cut to $189.00/Share From $193.00 by Truist Securities
Dow Jones · 3d ago
More
Webull provides a variety of real-time BIIB stock news. You can receive the latest news about Biogen Inc through multiple platforms. This information may help you make smarter investment decisions.
About BIIB
Biogen Inc. is a global biopharmaceutical company. The Company is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. It operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). It is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. It also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).